The role of open innovation in biomarker discovery

Journal Title: Advances in Precision Medicine - Year 2016, Vol 1, Issue 2

Abstract

Precision medicine aims to treat diseases with special consideration for the individual biological variability. Novel biomarkers (BM) are needed to predict therapeutic responses and to allow for the selection of suitable patients for treatment with certain drugs. However, the identification and validation of appropriate BMs is challenging. Close collaboration between different partners seems to be a key success factor. While the importance of partnerships and larger, well-established consortia in BM discovery such as the pharmaceutical industry and academic institutions is well understood and has been investigated in the past, the use of open-innovation models, also known as ‘crowd sourcing for biomarkers’, is still in its infancy. Crowd sourcing comprises of a — usually via internet — request for problem solution to an open group of users in a kind of an ‘open call’. The community (crowd) is asked to provide solutions. Since the application of the crowd sourcing method offers the possibility to collect as many as possible novel ideas from a broad community with different expertise, this approach is particularly promising for BM development. In this article we describe the first examples of open-innovation models, such as the ‘grants for targets’ (G4T) and biomarkers initiative ‘InnoCentive’ (innovation/incentive) platform. They may be a fruitful basis for collaborative BM development in the future.

Authors and Affiliations

Lilla Landeck, Monika Lessl, Andreas Busch, Matthias Gottwald and Khusru Asadullah

Keywords

Related Articles

What makes a good biomarker?

The last decade has seen an extraordinary amount of effort devoted in biomedical research to the field of biomarkers. There have been some notable successes with novel markers being adopted into clinical practice bringin...

Strategy to achieve biomarker-driven immunosuppression after solid organ transplantation by an academic-industry partnership within the European BIO-DrIM consortium

Solid organ transplantation has emerged as the “gold standard” therapy for end-stage organ failure as it improves both quality of life and survival. Despite the progress in short-term graft survival, that is closely asso...

Validation of novel multiplex technologies

Cytokine and chemokine levels in body fluid provide information of altered conditions in patients. The parallel analysis of multiple factors, such as cytokines, from small sample sizes is an interesting approach for the...

A classifier driven approach to find biomarkers for affective disorders from transcription profiles in blood

Gene expression profiles in blood are increasingly being used to identify biomarkers for different affective disorders. We have selected a set of 29 genes to generate expression profiles for healthy control subjects as w...

Identifying the active pharmaceutical ingredient from a mixture of fumaric acid esters for the treatment of psoriasis: Hints from in vitro investigations

A mixture of fumaric acid esters (FAEs) is approved for the oral therapy of psoriasis. However, for a long time the active ingredient of this mixture was unknown. We reviewed the in vitro data available for the different...

Download PDF file
  • EP ID EP679273
  • DOI -
  • Views 209
  • Downloads 0

How To Cite

Lilla Landeck, Monika Lessl, Andreas Busch, Matthias Gottwald and Khusru Asadullah (2016). The role of open innovation in biomarker discovery. Advances in Precision Medicine, 1(2), -. https://europub.co.uk/articles/-A-679273